1,707
Views
0
CrossRef citations to date
0
Altmetric
Neurology

Advanced Parkinson’s disease treatment patterns in Italy: an observational study interim analysis

ORCID Icon, , , , , , , , & show all
Article: 2315226 | Received 31 Oct 2023, Accepted 01 Feb 2024, Published online: 21 Feb 2024

Figures & data

Figure 1. Study design (the phase discussed in this manuscript is in the shaded box).

T0, study entry; Y, year prior to study entry.

Figure 1. Study design (the phase discussed in this manuscript is in the shaded box).T0, study entry; Y, year prior to study entry.

Table 1. Patient demographic and clinical characteristics.

Figure 2. Non-motor and motor symptoms of Parkinson’s disease (assessed by parts I/II of MDS-UPDRS). (A) part IA (physician assessed) nM-EDL; (B) part IB (patient assessed) nM-EDL; and (C) part II (patient assessed) motor experiences of daily living.

MDS-UPDRS: Unified Parkinson’s Disease Rating Scale by the Movement Disorder Society; nM-EDL: non-motor experiences of daily living.

Figure 2. Non-motor and motor symptoms of Parkinson’s disease (assessed by parts I/II of MDS-UPDRS). (A) part IA (physician assessed) nM-EDL; (B) part IB (patient assessed) nM-EDL; and (C) part II (patient assessed) motor experiences of daily living.MDS-UPDRS: Unified Parkinson’s Disease Rating Scale by the Movement Disorder Society; nM-EDL: non-motor experiences of daily living.

Figure 3. Types of motor fluctuations in the 2 years (Y2 and Y1) prior to study entry (T0).

Figure 3. Types of motor fluctuations in the 2 years (Y2 and Y1) prior to study entry (T0).

Figure 4. Improvements in motor and non-motor symptoms of wearing-off fluctuations (as assessed by the WOQ-19).

WOQ-19: 19-item Wearing-Off Questionnaire.

Figure 4. Improvements in motor and non-motor symptoms of wearing-off fluctuations (as assessed by the WOQ-19).WOQ-19: 19-item Wearing-Off Questionnaire.

Figure 5. Parkinson’s disease treatments 2 years prior (Y2 and Y1) to study entry (T0). (A) pharmacologic treatment (levodopa-carbidopa-entacapone was included in two classes - dopaminergic medications and COMT inhibitors); (B) dopaminergic medications (including concomitant use of >1 medication or combination); (C) dopamine agonists; (D) MAO-B inhibitors; and (E) COMT inhibitors (entacapone included levodopa-carbidopa-entacapone).

COMT: catechol-O-methyltransferase enzyme; MAO-B: monoamine oxidase B enzyme.

Figure 5. Parkinson’s disease treatments 2 years prior (Y2 and Y1) to study entry (T0). (A) pharmacologic treatment (levodopa-carbidopa-entacapone was included in two classes - dopaminergic medications and COMT inhibitors); (B) dopaminergic medications (including concomitant use of >1 medication or combination); (C) dopamine agonists; (D) MAO-B inhibitors; and (E) COMT inhibitors (entacapone included levodopa-carbidopa-entacapone).COMT: catechol-O-methyltransferase enzyme; MAO-B: monoamine oxidase B enzyme.
Supplemental material

Supplemental Material

Download MS Word (44.3 KB)

Data availability statement

The data supporting the findings of this study are available from the study sponsor (Bial Italy) upon reasonable request ([email protected]).